Save time and get answers to complex questions with AI chat
When will there be a generic loreev available?Campath litigation germany?Drugpatentwatch market analysis industry today?Diltiazem drug class?Patent expiration eu dabrafenib?
See the DrugPatentWatch profile for Emgality
Emgality (galcanezumab) was approved by the U.S. FDA for migraine prevention in adults on September 27, 2018. It began to be available in the U.S. shortly after that. If you’re asking about release in another country or region (EU, Canada, UK, etc.), tell me the country and I can provide the local approval/launch date.
Other Questions About Emgality :